Patents by Inventor Kashi Reddy Methuku

Kashi Reddy Methuku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GABAERGIC LIGANDS AND THEIR USES
    Publication number: 20190300534
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: February 25, 2019
    Publication date: October 3, 2019
    Inventors: James M. Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • Gabaergic ligands and their uses
    Patent number: 10259815
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 16, 2019
    Assignee: UWM Research Foundation, Inc.
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • GABAERGIC LIGANDS AND THEIR USES
    Publication number: 20180065967
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 8, 2018
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li